[{"id":"41656404-5e54-4216-8a7c-b90090a6806a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06791460","created_at":"2025-02-25T18:53:09.303Z","updated_at":"2025-02-25T18:53:09.303Z","phase":"Phase 2/3","brief_title":"Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer","source_id_and_acronym":"NCT06791460","lead_sponsor":"Obstetrics \u0026 Gynecology Hospital of Fudan University","biomarkers":" CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • AiRuiLi (adebrelimab) • mirabegron"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 296","initiation":"Initiation: 02/15/2025","start_date":" 02/15/2025","primary_txt":" Primary completion: 02/14/2028","primary_completion_date":" 02/14/2028","study_txt":" Completion: 02/14/2030","study_completion_date":" 02/14/2030","last_update_posted":"2025-01-24"},{"id":"a575da2d-72a1-4264-aaeb-fbc4aebb6b41","acronym":"","url":"https://clinicaltrials.gov/study/NCT06766019","created_at":"2025-02-26T07:14:21.939Z","updated_at":"2025-02-26T07:14:21.939Z","phase":"Phase 2","brief_title":"Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer","source_id_and_acronym":"NCT06766019","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • AiRuiLi (adebrelimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-01-09"},{"id":"b3d0abdf-0279-4d36-aa6d-69fe2e62ba80","acronym":"SHR-1316-SCLC-LN-001","url":"https://clinicaltrials.gov/study/NCT06480864","created_at":"2025-02-26T07:35:04.037Z","updated_at":"2025-02-26T07:35:04.037Z","phase":"","brief_title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT06480864 - SHR-1316-SCLC-LN-001","lead_sponsor":"Yunpeng Liu","biomarkers":" PD-L1 • IL6 • IL10","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 08/09/2024","start_date":" 08/09/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-06"},{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"066af9ab-9fbe-40c8-8b39-9e712dd6f439","acronym":"","url":"https://clinicaltrials.gov/study/NCT06600841","created_at":"2025-02-26T13:35:01.576Z","updated_at":"2025-02-26T13:35:01.576Z","phase":"Phase 2","brief_title":"Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer","source_id_and_acronym":"NCT06600841","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" HRD","pipe":" | ","alterations":" PD-L1 expression • HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-09-19"},{"id":"07acdaee-81fa-42a2-b6a8-44ffa1343ca1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06385678","created_at":"2024-04-26T18:53:22.008Z","updated_at":"2024-07-02T16:35:07.335Z","phase":"Phase 1/2","brief_title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT06385678","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • AiRuiLi (adebrelimab) • HRS-4642 • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-04-26"},{"id":"0f4f4db7-864a-4af4-9ed3-894c0ed55bd1","acronym":"HSBRT2401","url":"https://clinicaltrials.gov/study/NCT06261125","created_at":"2024-02-15T17:26:46.872Z","updated_at":"2024-07-02T16:35:15.217Z","phase":"Phase 2","brief_title":"Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)","source_id_and_acronym":"NCT06261125 - HSBRT2401","lead_sponsor":"Mian XI","biomarkers":" IL6 • IL2RA • CD40","pipe":"","alterations":" ","tags":["IL6 • IL2RA • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/10/2024","start_date":" 03/10/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-03-12"},{"id":"a12b006f-dc84-4bc8-80cc-7523ed0f98b1","acronym":"ENIGMA","url":"https://clinicaltrials.gov/study/NCT05205200","created_at":"2022-01-25T16:54:16.056Z","updated_at":"2024-07-02T16:35:20.272Z","phase":"Phase 2","brief_title":"Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02","source_id_and_acronym":"NCT05205200 - ENIGMA","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR • SMARCA2","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR • SMARCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • fulvestrant • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 06/06/2022","start_date":" 06/06/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-02-08"},{"id":"7e1faa69-bedf-4082-92b9-4c95c81a5274","acronym":"","url":"https://clinicaltrials.gov/study/NCT05753826","created_at":"2023-10-19T19:12:44.189Z","updated_at":"2024-07-02T16:35:20.738Z","phase":"Phase 2","brief_title":"Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.","source_id_and_acronym":"NCT05753826","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-02-06"},{"id":"e41c3c99-030c-4fd3-9c18-39f57f967dea","acronym":"","url":"https://clinicaltrials.gov/study/NCT06231017","created_at":"2024-01-30T16:20:10.737Z","updated_at":"2024-07-02T16:35:21.713Z","phase":"Phase 2","brief_title":"Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer","source_id_and_acronym":"NCT06231017","lead_sponsor":"The First Affiliated Hospital of Zhengzhou University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 01/19/2025","primary_completion_date":" 01/19/2025","study_txt":" Completion: 01/19/2026","study_completion_date":" 01/19/2026","last_update_posted":"2024-01-30"},{"id":"02eaa568-b3ce-4a18-a3ca-9ab426a744ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05132790","created_at":"2021-11-24T18:55:39.081Z","updated_at":"2024-07-02T16:35:24.664Z","phase":"","brief_title":"Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment","source_id_and_acronym":"NCT05132790","lead_sponsor":"Shengjing Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • albumin-bound paclitaxel • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-03"},{"id":"2cde167a-062e-41d7-8b72-491425021645","acronym":"","url":"https://clinicaltrials.gov/study/NCT06149767","created_at":"2023-11-29T16:15:24.328Z","updated_at":"2024-07-02T16:35:27.657Z","phase":"Phase 2","brief_title":"Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer","source_id_and_acronym":"NCT06149767","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • AiRuiLi (adebrelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2023-11-29"},{"id":"5992e1f2-63b6-45f1-8c22-41240b0aaf81","acronym":"","url":"https://clinicaltrials.gov/study/NCT03995472","created_at":"2022-07-14T16:59:43.900Z","updated_at":"2024-07-02T16:35:35.528Z","phase":"Phase 1","brief_title":"A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors","source_id_and_acronym":"NCT03995472","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiLi (adebrelimab) • SHR-1501"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 02/14/2020","start_date":" 02/14/2020","primary_txt":" Primary completion: 01/12/2023","primary_completion_date":" 01/12/2023","study_txt":" Completion: 01/12/2023","study_completion_date":" 01/12/2023","last_update_posted":"2023-09-27"},{"id":"aee25c39-e431-4c28-aa25-5f21ea54d750","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942378","created_at":"2023-07-12T15:08:56.192Z","updated_at":"2024-07-02T16:35:43.394Z","phase":"Phase 1","brief_title":"A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05942378","lead_sponsor":"Fudan University","biomarkers":" IL6 • IL2 • IL10","pipe":"","alterations":" ","tags":["IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiLi (adebrelimab) • HRXG-K-1939"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-12"},{"id":"b17610a4-7f1e-4ca3-bde1-2677610463ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05932264","created_at":"2023-07-06T16:10:07.113Z","updated_at":"2024-07-02T16:35:43.864Z","phase":"Phase 2","brief_title":"Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05932264","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • BRAF • ALK • TP53 • ROS1","pipe":" | ","alterations":" TP53 mutation • ALK positive • TP53 R175H • TP53 R248Q • TP53 Y220C • TP53 R273H • TP53 R273C","tags":["EGFR • BRAF • ALK • TP53 • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • TP53 R175H • TP53 R248Q • TP53 Y220C • TP53 R273H • TP53 R273C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-06"},{"id":"6b8da668-3452-4f5c-9ff3-8baba01ae0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634058","created_at":"2021-01-19T20:37:05.920Z","updated_at":"2024-07-02T16:35:56.030Z","phase":"Phase 2","brief_title":"PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment","source_id_and_acronym":"NCT04634058","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiLi (adebrelimab) • Tabosun (ipilimumab N01 injection)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-02-08"},{"id":"8c030dcd-ba25-4c02-bc96-82bf4e0fdfaf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05416775","created_at":"2022-06-13T15:55:33.173Z","updated_at":"2024-07-02T16:36:05.116Z","phase":"Phase 1/2","brief_title":"Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05416775","lead_sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 08/15/2022","start_date":" 08/15/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2022-08-19"},{"id":"6ffee92c-c68c-41f1-a318-407eee56b06f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03133247","created_at":"2022-07-12T13:57:20.127Z","updated_at":"2024-07-02T16:36:07.417Z","phase":"Phase 1","brief_title":"A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients","source_id_and_acronym":"NCT03133247","lead_sponsor":"Atridia Pty Ltd.","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiLi (adebrelimab)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 04/09/2019","primary_completion_date":" 04/09/2019","study_txt":" Completion: 07/05/2019","study_completion_date":" 07/05/2019","last_update_posted":"2022-07-12"},{"id":"d1d03cb1-22ea-4326-bd9c-c043e0ef8215","acronym":"","url":"https://clinicaltrials.gov/study/NCT04303988","created_at":"2021-01-18T20:52:28.216Z","updated_at":"2024-07-02T16:36:48.762Z","phase":"Phase 2","brief_title":"A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.","source_id_and_acronym":"NCT04303988","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • temozolomide • Irene (pyrotinib) • AiRuiLi (adebrelimab)"],"overall_status":"Unknown status","enrollment":" Enrollment 59","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 01/30/2022","study_completion_date":" 01/30/2022","last_update_posted":"2020-03-11"}]